Clean Cancer Targets for Better Therapeutics: Going Beyond the Proteome
- Expanding the ADC target space through clean targeting of all major epithelial cancers through surface exposed glyco-epitopes
- Developing a series of cancer specific antibodies developed as payload- and platform-agnostic glyco-peptide targeting ADCs
- Exploring how GO’s glyco-epitope ADCs provide clean cancer targeting, reduced on-target/off-tumor toxicity, and potent in vivo efficacy and safety